Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Antibe Therapeutics Inc. has secured temporary protection from its creditors through the Companies’ Creditors Arrangement Act, with Deloitte Restructuring Inc. overseeing the process as the court-appointed Monitor. The protection, which halts enforcement actions such as the US$24 million payment to Nuance Pharma, will last until April 18, 2024, when Antibe will seek an extension to resolve issues with a U.S. FDA hold on a planned trial. Following these events, trading of Antibe’s common shares was suspended on the Toronto Stock Exchange.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.